JP2011519941A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519941A5 JP2011519941A5 JP2011508584A JP2011508584A JP2011519941A5 JP 2011519941 A5 JP2011519941 A5 JP 2011519941A5 JP 2011508584 A JP2011508584 A JP 2011508584A JP 2011508584 A JP2011508584 A JP 2011508584A JP 2011519941 A5 JP2011519941 A5 JP 2011519941A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- compound
- formula
- cancer
- erbb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 102000056372 ErbB-3 Receptor Human genes 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- -1 morpholino, piperidinyl Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N COCCOc1cc2c(Nc3cccc(C#C)c3)ncnc2cc1OCCOC Chemical compound COCCOc1cc2c(Nc3cccc(C#C)c3)ncnc2cc1OCCOC AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5032208P | 2008-05-05 | 2008-05-05 | |
| US61/050,322 | 2008-05-05 | ||
| PCT/US2009/042768 WO2009137429A1 (en) | 2008-05-05 | 2009-05-05 | Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011519941A JP2011519941A (ja) | 2011-07-14 |
| JP2011519941A5 true JP2011519941A5 (enExample) | 2012-06-21 |
Family
ID=41257222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011508584A Pending JP2011519941A (ja) | 2008-05-05 | 2009-05-05 | ｃＭＥＴおよびＡＸＬの阻害剤並びにＥｒｂＢ阻害剤を使用するガンの治療方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20090274693A1 (enExample) |
| EP (1) | EP2274304A4 (enExample) |
| JP (1) | JP2011519941A (enExample) |
| KR (1) | KR20110004462A (enExample) |
| CN (1) | CN102083824A (enExample) |
| AR (1) | AR071631A1 (enExample) |
| AU (1) | AU2009244453B2 (enExample) |
| BR (1) | BRPI0912582A2 (enExample) |
| CA (1) | CA2723699A1 (enExample) |
| CL (1) | CL2009001063A1 (enExample) |
| EA (1) | EA020779B1 (enExample) |
| IL (1) | IL209057A0 (enExample) |
| MX (1) | MX2010012101A (enExample) |
| PE (1) | PE20091832A1 (enExample) |
| SG (1) | SG190623A1 (enExample) |
| TW (1) | TW201006829A (enExample) |
| UY (1) | UY31800A (enExample) |
| WO (1) | WO2009137429A1 (enExample) |
| ZA (1) | ZA201007722B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2833706C (en) | 2005-11-11 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
| TW201920110A (zh) | 2009-01-16 | 2019-06-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
| ES2549769T3 (es) | 2009-03-25 | 2015-11-02 | Genentech, Inc. | Anticuerpos anti-FGFR3 y métodos que emplean los mismos |
| SI2451445T1 (sl) | 2009-07-06 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino |
| TW201106972A (en) * | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
| WO2011014872A2 (en) * | 2009-07-31 | 2011-02-03 | The Johns Hopkins University | Compositions and methods for diagnosing, treating or preventing neoplasias |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| KR101806323B1 (ko) * | 2009-11-13 | 2017-12-07 | 다이이치 산쿄 유럽 게엠베하 | Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법 |
| WO2012009722A1 (en) | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| ME02637B (me) | 2010-08-20 | 2017-06-20 | Novartis Ag | Antitela za receptor 3 faktora rasta epiderma (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| HUE045810T2 (hu) | 2010-09-27 | 2020-01-28 | Exelixis Inc | MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére |
| SG191230A1 (en) * | 2010-12-23 | 2013-07-31 | Nestec Sa | Drug selection for malignant cancer therapy using antibody-based arrays |
| CN102532109B (zh) * | 2010-12-27 | 2015-05-13 | 浙江海正药业股份有限公司 | 一种拉帕替尼及其盐的合成方法 |
| CN102093421B (zh) * | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| TW201309650A (zh) | 2011-02-10 | 2013-03-01 | 艾克塞里克斯公司 | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| EP2704717A1 (en) * | 2011-05-02 | 2014-03-12 | Exelixis, Inc. | Method of treating cancer and bone cancer pain |
| GEP201606523B (en) | 2011-09-22 | 2016-08-10 | Exelixis Inc | Method for treating osteoporosis |
| PL2768796T3 (pl) | 2011-10-20 | 2020-05-18 | Exelixis, Inc. | Sposób wytwarzania pochodnych chinoliny |
| EA023521B1 (ru) | 2011-11-14 | 2016-06-30 | Сефалон, Инк. | ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ |
| CN108341873B (zh) * | 2011-12-05 | 2022-03-25 | 诺华股份有限公司 | 表皮生长因子受体3(her3)的抗体 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| SG11201404505PA (en) | 2012-01-31 | 2014-10-30 | Daiichi Sankyo Co Ltd | Pyridone derivative |
| HK1207587A1 (en) | 2012-05-02 | 2016-02-05 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| CN103664879A (zh) * | 2012-09-17 | 2014-03-26 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
| CN103705521A (zh) * | 2012-09-28 | 2014-04-09 | 韩冰 | 一类治疗脑梗塞的化合物及其用途 |
| WO2014093750A1 (en) * | 2012-12-14 | 2014-06-19 | Glaxosmithkline Llc | Method of administration and treatment |
| GEP20196995B (en) | 2013-03-15 | 2019-07-25 | Inc Exelixis | Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
| KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
| ES2927651T3 (es) | 2013-04-04 | 2022-11-10 | Exelixis Inc | Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer |
| TWI649308B (zh) * | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
| US10196446B2 (en) | 2013-10-14 | 2019-02-05 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
| HUE049437T2 (hu) | 2014-02-04 | 2020-09-28 | Astellas Pharma Inc | Hatóanyagként heterociklusos diamino-karboxamid vegyületet tartalmazó gyógyászati készítmény |
| EA032757B1 (ru) | 2014-02-14 | 2019-07-31 | Экселиксис, Инк. | Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения |
| CN106255499A (zh) | 2014-03-17 | 2016-12-21 | 埃克塞里艾克西斯公司 | 卡博替尼制剂的给药 |
| NZ725361A (en) * | 2014-04-03 | 2022-09-30 | Merck Patent Gmbh | Combinations of cancer therapeutics |
| KR102223502B1 (ko) | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
| TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| EA033834B1 (ru) | 2014-07-31 | 2019-11-29 | Exelixis Inc | Способ получения кабозантиниба, меченного фтором-18, и его аналогов |
| MA40457A (fr) | 2014-08-05 | 2017-06-14 | Exelixis Inc | Combinaison de médicaments pour traiter le myélome multiple |
| WO2016104617A1 (ja) | 2014-12-25 | 2016-06-30 | 小野薬品工業株式会社 | キノリン誘導体 |
| FR3039401B1 (fr) * | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
| CN106467541B (zh) * | 2015-08-18 | 2019-04-05 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
| US11141413B2 (en) | 2016-04-15 | 2021-10-12 | Exelixis, Inc. | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
| WO2017223180A2 (en) | 2016-06-21 | 2017-12-28 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type iii domain binding molecules |
| CN110437145A (zh) * | 2016-09-13 | 2019-11-12 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| CN107235897B (zh) * | 2016-09-27 | 2019-08-16 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| WO2018111976A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Pd-l1 binding fibronectin type iii domains |
| KR102568559B1 (ko) | 2016-12-14 | 2023-08-18 | 얀센 바이오테크 인코포레이티드 | Cd8a-결합 섬유결합소 iii형 도메인 |
| WO2018111978A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| KR102571911B1 (ko) | 2017-01-26 | 2023-08-28 | 오노 야꾸힝 고교 가부시키가이샤 | 퀴놀린 유도체의 에탄술폰산염 |
| DK3583943T3 (da) | 2017-02-15 | 2024-10-14 | Taiho Pharmaceutical Co Ltd | Farmaceutisk sammensætning |
| EP3682882A4 (en) | 2017-09-08 | 2021-06-02 | Taiho Pharmaceutical Co., Ltd. | ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER |
| US11826363B2 (en) | 2017-10-13 | 2023-11-28 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient |
| TWI787523B (zh) | 2018-06-15 | 2022-12-21 | 漢達生技醫藥股份有限公司 | 達沙替尼十二烷基硫酸鹽之結晶 |
| EP3914356A1 (en) * | 2019-01-25 | 2021-12-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| CN114786682B (zh) | 2019-10-14 | 2024-07-16 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| WO2021076543A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| CN115073367A (zh) * | 2021-03-16 | 2022-09-20 | 南京科默生物医药有限公司 | 一种用作axl抑制剂的抗肿瘤化合物及其用途 |
| JP2024517610A (ja) | 2021-04-14 | 2024-04-23 | アロ・バイオセラピューティクス・カンパニー | Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン |
| KR20240031947A (ko) | 2021-04-14 | 2024-03-08 | 에이알오 바이오테라퓨틱스 컴패니 | Fn3 도메인-시르나 접합체 및 이의 용도 |
| KR20250136810A (ko) | 2023-01-31 | 2025-09-16 | 한다 온콜로지, 엘엘씨 | 개선된 카보잔티닙 조성물 및 사용 방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141576B2 (en) * | 2001-01-16 | 2006-11-28 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
| EP2210607B1 (en) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| ITRM20030475A1 (it) * | 2003-10-15 | 2005-04-16 | Sipa Societa Industrializzazione P Rogettazione E | Impianto e metodo per il condizionamento termico di oggetti |
| UA96139C2 (uk) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
| EP1962903B1 (en) * | 2005-12-15 | 2013-03-13 | MedImmune Limited | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| WO2007081978A2 (en) * | 2006-01-11 | 2007-07-19 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor / c-met activity |
| WO2008076415A1 (en) * | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| CA2683559C (en) * | 2007-04-13 | 2019-09-24 | Dana Farber Cancer Institute, Inc. | Methods for treating cancer resistant to erbb therapeutics |
| ES2541051T3 (es) * | 2007-05-17 | 2015-07-15 | Genentech, Inc. | Estructuras cristalinas de fragmentos de neuropilina y complejos neuropilina-anticuerpo |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| EP2190429B1 (en) * | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
-
2009
- 2009-04-30 UY UY0001031800A patent/UY31800A/es not_active Application Discontinuation
- 2009-05-04 PE PE2009000602A patent/PE20091832A1/es not_active Application Discontinuation
- 2009-05-04 TW TW098114669A patent/TW201006829A/zh unknown
- 2009-05-04 CL CL2009001063A patent/CL2009001063A1/es unknown
- 2009-05-05 EP EP09743415A patent/EP2274304A4/en not_active Withdrawn
- 2009-05-05 EA EA201071268A patent/EA020779B1/ru not_active IP Right Cessation
- 2009-05-05 AR ARP090101611A patent/AR071631A1/es unknown
- 2009-05-05 AU AU2009244453A patent/AU2009244453B2/en not_active Ceased
- 2009-05-05 KR KR1020107027183A patent/KR20110004462A/ko not_active Ceased
- 2009-05-05 CN CN2009801261595A patent/CN102083824A/zh active Pending
- 2009-05-05 SG SG2013033709A patent/SG190623A1/en unknown
- 2009-05-05 CA CA2723699A patent/CA2723699A1/en not_active Abandoned
- 2009-05-05 JP JP2011508584A patent/JP2011519941A/ja active Pending
- 2009-05-05 BR BRPI0912582-5A patent/BRPI0912582A2/pt not_active IP Right Cessation
- 2009-05-05 WO PCT/US2009/042768 patent/WO2009137429A1/en not_active Ceased
- 2009-05-05 MX MX2010012101A patent/MX2010012101A/es not_active Application Discontinuation
- 2009-05-05 US US12/435,473 patent/US20090274693A1/en not_active Abandoned
-
2010
- 2010-10-28 ZA ZA2010/07722A patent/ZA201007722B/en unknown
- 2010-11-01 IL IL209057A patent/IL209057A0/en unknown
-
2013
- 2013-01-29 US US13/753,146 patent/US20130150363A1/en not_active Abandoned
- 2013-01-29 US US13/753,031 patent/US20130142790A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523159A5 (enExample) | ||
| JP2023542066A5 (enExample) | ||
| AR071631A1 (es) | Uso de un compuesto de quinilinil -4-oxi- fenil- ciclopropildicarboxamida y un inhibidor de erbb para preparar un medicamento util para el tratamiento de canceres | |
| RU2013143381A (ru) | Фармацевтически приемлемая соль (е)-n-[4-[[3-хлор-4-(2-пиридилметокси)фенил]амино]-3-циано-7-этокси-6-хинолил]3-[(2r)-1-метилпирролидин-2-ил]проп-2-енамида, способ ее получения и ее медицинское применение | |
| JP2014528464A5 (enExample) | ||
| JP2012504628A5 (enExample) | ||
| JP2009507909A5 (enExample) | ||
| JP2018504418A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| JP2014528433A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2014533284A5 (enExample) | ||
| JP2013510120A5 (enExample) | ||
| JP2016053042A5 (enExample) | ||
| JP2015534577A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| JP2017510661A5 (enExample) | ||
| JP2011516427A5 (enExample) | ||
| JP2015536986A5 (enExample) | ||
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения | |
| JP2018076369A (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JP2013520431A5 (enExample) | ||
| RU2012139825A (ru) | Антагонисты неурегулина и применение их в лечении злокачественного новообразования | |
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| JP2012520321A5 (enExample) |